OncoMatch/Clinical Trials/NCT05814354
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial
Is NCT05814354 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including SHR-A1811 and Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel for breast cancer.
Treatment: SHR-A1811 · Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel — The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) low expression (IHC 2+/ISH- or IHC 1+ [ISH- or untested]) (IHC 2+/ISH- or IHC 1+ (ISH- or untested))
Low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested).
Required: ESR1 positive
HR-positive breast cancer
Disease stage
Metastatic disease required
Prior therapy
Must have received: endocrine therapy — metastatic
Lab requirements
Blood counts
protocol-defined adequate bone marrow function
Kidney function
protocol-defined adequate renal function
Liver function
protocol-defined adequate hepatic function
Cardiac function
protocol-defined adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify